Fitusiran in haemophilia: a breakthrough drug with many unknowns

Lancet. 2023 Apr 29;401(10386):1400-1401. doi: 10.1016/S0140-6736(23)00514-7. Epub 2023 Mar 29.

Authors

Flora Peyvandi¹, Isabella Garagiola², Maria Abbattista²

Affiliations

¹ Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Department of Transplantation, Università degli Studi di Milano, Milan 20122, Italy. Electronic address: flora.peyvandi@unimi.it.
² Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.

PMID: 37003290
DOI: 10.1016/S0140-6736(23)00514-7

No abstract available

Publication types

Comment

MeSH terms

Acetylgalactosamine
Factor VIII
Hemophilia A* / complications
Hemophilia A* / drug therapy
Hemophilia B*
Humans
RNA, Small Interfering

Substances

fitusiran
Acetylgalactosamine
RNA, Small Interfering
Factor VIII